RxDoctor Payments Data

William King, MD

Internal Medicine · Los Angeles, CANPI 1427079250

Payments from drug & device makers

$226,553in general payments, 2019–2025

Across 557 payments — averaging $406.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$157K
  • Gilead$65K
  • GSK$733
  • Bayer$501
  • AbbVie$430
  • Merck$422
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$44,32020%
  • Speaking & faculty fees$141,92863%
  • Travel & lodging$24,28311%
  • Food & beverage$15,7657%
  • Education$2580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$226,553 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$60,364
Medicare patients
98
Services billed
5,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala86$334,951
DovatoDolutegravir Sodium/Lamivudine71$213,024
JardianceEmpagliflozin99$103,113
Trelegy ElliptaFluticasone/Umeclidin/Vilanter140$94,222
EliquisApixaban81$92,540
LinzessLinaclotide66$60,380
TriumeqAbacavir/Dolutegravir/Lamivudi13$47,743
OzempicSemaglutide39$45,347
TivicayDolutegravir Sodium13$35,275
KerendiaFinerenone14$23,402
TradjentaLinagliptin16$19,653
FarxigaDapagliflozin Propanediol13$18,840
TrulicityDulaglutide17$16,979
Soliqua 100-33Insulin Glargine/Lixisenatide27$16,793
SynjardyEmpagliflozin/Metformin Hcl11$15,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$64,755$334,95186 claims
Viiv Healthcare CompanyDovato, Triumeq, Tivicay$157,247$296,04297 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Jentadueto Xr$160$143,477138 claims
GSKTrelegy Ellipta$733$94,222140 claims
PfizerEliquis$328$92,54081 claims
AbbVieLinzess$430$60,38066 claims
Novo NordiskOzempic$40$45,34739 claims
Lilly USA, LLCTrulicity, Mounjaro$193$29,78029 claims
BayerKerendia$501$23,40214 claims
AstraZenecaFarxiga, Symbicort$193$22,88033 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$35$16,79327 claims
NovartisEntresto$52$12,72312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →